<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39372768</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Intranasal parainfluenza virus-vectored vaccine expressing SARS-CoV-2 spike protein of Delta or Omicron B.1.1.529 induces mucosal and systemic immunity and protects hamsters against homologous and heterologous challenge.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2024.09.12.612598</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2024.09.12.612598</ELocationID><Abstract><AbstractText>The continuous emergence of new SARS-CoV-2 variants requires that COVID vaccines be updated to match circulating strains. We generated B/HPIV3-vectored vaccines expressing 6P-stabilized S protein of the ancestral, B.1.617.2/Delta, or B.1.1.529/Omicron variants as pediatric vaccines for intranasal immunization against HPIV3 and SARS-CoV-2 and characterized these in hamsters. Following intranasal immunization, these B/HPIV3 vectors replicated in the upper and lower respiratory tract and induced mucosal and serum anti-S IgA and IgG. B/HPIV3 expressing ancestral or B.1.617.2/Delta-derived S-6P induced serum antibodies that effectively neutralized SARS-CoV-2 of the ancestral and B.1.617.2/Delta lineages, while the cross-neutralizing potency of B.1.1.529/Omicron S-induced antibodies was lower. Despite the lower cross-neutralizing titers induced by B/HPIV3 expressing S-6P from B.1.1.529/Omicron, a single intranasal dose of all three versions of B/HPIV3 vectors was protective against matched or heterologous WA1/2020, B.1.617.2/Delta or BA.1 (B.1.1.529.1)/Omicron challenge; hamsters were protected from challenge virus replication in the lungs, while low levels of challenge virus were detectable in the upper respiratory tract of a small number of animals. Immunization also protected against lung inflammatory response after challenge, with mild inflammatory cytokine induction associated with the slightly lower level of cross-protection of WA1/2020 and B.1.617.2/Delta variants against the BA.1/Omicron variant. Serum antibodies elicited by all vaccine candidates were broadly reactive against 20 antigenic variants, but the antigenic breadth of antibodies elicited by B/HPIV3-expressed S-6P from the ancestral or B.1.617.2/Delta variant exceeded that of the S-6P B.1.1.529/Omicron expressing vector. These results will guide development of intranasal B/HPIV3 vectors with S antigens matching circulating SARS-CoV-2 variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hong-Su</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Yumiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Celia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luongo</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xueqiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Jaclyn A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Eleanor F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Reed F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>SARS-CoV-2 Virology Core, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>I-Ting</ForeName><Initials>IT</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Peter D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchholz</LastName><ForeName>Ursula J</ForeName><Initials>UJ</Initials><AffiliationInfo><Affiliation>RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Nouën</LastName><ForeName>Cyril</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5719-4112</Identifier><AffiliationInfo><Affiliation>RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA AI001298</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIC AI005111</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo><CoiStatement>Competing Interest U.J.B., C.L., X.L, and C.LN. are inventors on the provisional patent application number 63/180,534, entitled “Recombinant chimeric bovine/human parainfluenza virus 3 expressing SARS-CoV-2 spike protein and its use”, filed by the United States of America, Department of Health and Human Services</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39372768</ArticleId><ArticleId IdType="pmc">PMC11451599</ArticleId><ArticleId IdType="doi">10.1101/2024.09.12.612598</ArticleId><ArticleId IdType="pii">2024.09.12.612598</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO. COVID-19 Epidemiological Update. World Health Organization, 2024 17 May 2024. Report No.</Citation></Reference><Reference><Citation>Waghmare A, Hijano DR. SARS-CoV-2 Infection and COVID-19 in Children. Clin Chest Med. 2023;44(2):359–71. doi: 10.1016/j.ccm.2022.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccm.2022.11.014</ArticleId><ArticleId IdType="pmc">PMC9678836</ArticleId><ArticleId IdType="pubmed">37085225</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi DS, Whitaker M, Marks KJ, Anglin O, Milucky J, Patel K, et al. Hospitalizations of Children Aged 5–11 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(16):574–81. doi: 10.15585/mmwr.mm7116e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7116e1</ArticleId><ArticleId IdType="pmc">PMC9042359</ArticleId><ArticleId IdType="pubmed">35446827</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Most ZM, Perl TM, Diaz MI, Casazza JA, Saleh S, et al. Incidence and Risk Factors for Severe Outcomes in Pediatric Patients With COVID-19. Hosp Pediatr. 2023;13(5):450–62. doi: 10.1542/hpeds.2022-006833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/hpeds.2022-006833</ArticleId><ArticleId IdType="pubmed">37038904</ArticleId></ArticleIdList></Reference><Reference><Citation>Aparicio C, Willis ZI, Nakamura MM, Wolf J, Little C, Maron GM, et al. Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis. J Pediatric Infect Dis Soc. 2024. doi: 10.1093/jpids/piae052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piae052</ArticleId><ArticleId IdType="pubmed">38780125</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta RK, Topol EJ. COVID-19 vaccine breakthrough infections. Science. 2021;374(6575):1561–2. doi: 10.1126/science.abl8487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl8487</ArticleId><ArticleId IdType="pubmed">34941414</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddle KJ, Krasilnikova LA, Moreno GK, Schaffner SF, Vostok J, Fitzgerald NA, et al. Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. Cell. 2022;185(3):485–92 e10. doi: 10.1016/j.cell.2021.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.027</ArticleId><ArticleId IdType="pmc">PMC8695126</ArticleId><ArticleId IdType="pubmed">35051367</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DY, Xu Y, Gu Y, Zeng D, Sunny SK, Moore Z. Durability of Bivalent Boosters against Omicron Subvariants. N Engl J Med. 2023;388(19):1818–20. doi: 10.1056/NEJMc2302462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2302462</ArticleId><ArticleId IdType="pmc">PMC10120009</ArticleId><ArticleId IdType="pubmed">37043647</ArticleId></ArticleIdList></Reference><Reference><Citation>Moliva JI, Andrew SF, Flynn BJ, Wagner DA, Foulds KE, Gagne M, et al. Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates. bioRxiv. 2023. doi: 10.1101/2023.11.22.567930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.11.22.567930</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne M, Flynn BJ, Andrew SF, Marquez J, Flebbe DR, Mychalowych A, et al. Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates. Nat Immunol. 2024. doi: 10.1038/s41590-024-01951-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-024-01951-5</ArticleId><ArticleId IdType="pmc">PMC11436372</ArticleId><ArticleId IdType="pubmed">39227514</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chamblee M, Xu J, Qu P, Shamseldin MM, Yoo SJ, et al. Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective. Nat Commun. 2024;15(1):5589. doi: 10.1038/s41467-024-49443-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-49443-2</ArticleId><ArticleId IdType="pmc">PMC11222507</ArticleId><ArticleId IdType="pubmed">38961063</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K, Wegmann F, Aid M, Sciacca M, Liu J, Hachmann NP, et al. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques. Nature. 2024;626(7998):385–91. doi: 10.1038/s41586-023-06951-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06951-3</ArticleId><ArticleId IdType="pmc">PMC10849944</ArticleId><ArticleId IdType="pubmed">38096903</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt AC, McAuliffe JM, Huang A, Surman SR, Bailly JE, Elkins WR, et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol. 2000;74(19):8922–9. doi: 10.1128/jvi.74.19.8922-8929.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.74.19.8922-8929.2000</ArticleId><ArticleId IdType="pmc">PMC102087</ArticleId><ArticleId IdType="pubmed">10982335</ArticleId></ArticleIdList></Reference><Reference><Citation>Karron RA, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL, et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine. 2012;30(26):3975–81. doi: 10.1016/j.vaccine.2011.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.022</ArticleId><ArticleId IdType="pmc">PMC3509782</ArticleId><ArticleId IdType="pubmed">22178099</ArticleId></ArticleIdList></Reference><Reference><Citation>Skiadopoulos MH, Schmidt AC, Riggs JM, Surman SR, Elkins WR, St Claire M, et al. Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic. J Virol. 2003;77(2):1141–8. doi: 10.1128/jvi.77.2.1141-1148.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.77.2.1141-1148.2003</ArticleId><ArticleId IdType="pmc">PMC140817</ArticleId><ArticleId IdType="pubmed">12502830</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang B, Matsuoka Y, Le Nouen C, Liu X, Herbert R, Swerczek J, et al. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV. J Virol. 2020;95(2). doi: 10.1128/JVI.01512-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01512-20</ArticleId><ArticleId IdType="pmc">PMC7944453</ArticleId><ArticleId IdType="pubmed">33115876</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang B, Munir S, Amaro-Carambot E, Surman S, Mackow N, Yang L, et al. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection. J Virol. 2014;88(8):4237–50. doi: 10.1128/JVI.03481-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03481-13</ArticleId><ArticleId IdType="pmc">PMC3993740</ArticleId><ArticleId IdType="pubmed">24478424</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang B, Ngwuta JO, Herbert R, Swerczek J, Dorward DW, Amaro-Carambot E, et al. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector. J Virol. 2016;90(21):10022–38. doi: 10.1128/JVI.01196-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01196-16</ArticleId><ArticleId IdType="pmc">PMC5068507</ArticleId><ArticleId IdType="pubmed">27581977</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang B, Ngwuta JO, Surman S, Kabatova B, Liu X, Lingemann M, et al. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate. J Virol. 2017;91(15). doi: 10.1128/JVI.00189-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00189-17</ArticleId><ArticleId IdType="pmc">PMC5651718</ArticleId><ArticleId IdType="pubmed">28539444</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang RS, Spaete RR, Thompson MW, MacPhail M, Guzzetta JM, Ryan PC, et al. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine. 2008;26(50):6373–82. doi: 10.1016/j.vaccine.2008.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.09.018</ArticleId><ArticleId IdType="pubmed">18822334</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F, et al. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J. 2012;31(2):109–14. doi: 10.1097/INF.0b013e31823386f1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e31823386f1</ArticleId><ArticleId IdType="pubmed">21926667</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–3. doi: 10.1126/science.abb2507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2507</ArticleId><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, Goldsmith JA, Schaub JM, DiVenere AM, Kuo HC, Javanmardi K, et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020;369(6510):1501–5. doi: 10.1126/science.abd0826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0826</ArticleId><ArticleId IdType="pmc">PMC7402631</ArticleId><ArticleId IdType="pubmed">32703906</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Luongo C, Matsuoka Y, Park HS, Santos C, Yang L, et al. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters. Proc Natl Acad Sci U S A. 2021;118(50). doi: 10.1073/pnas.2109744118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2109744118</ArticleId><ArticleId IdType="pmc">PMC8685679</ArticleId><ArticleId IdType="pubmed">34876520</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Park HS, Matsuoka Y, Santos C, Yang L, Luongo C, et al. Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters. PLoS Pathog. 2023;19(6):e1011057. doi: 10.1371/journal.ppat.1011057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1011057</ArticleId><ArticleId IdType="pmc">PMC10325082</ArticleId><ArticleId IdType="pubmed">37352333</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Nouën C, Nelson CE, Liu X, Park HS, Matsuoka Y, Luongo C, et al. Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys. Cell. 2022;185(25):4811–25.e17. doi: 10.1016/j.cell.2022.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.11.006</ArticleId><ArticleId IdType="pmc">PMC9684001</ArticleId><ArticleId IdType="pubmed">36423629</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–84.e15. doi: 10.1016/j.cell.2021.12.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.046</ArticleId><ArticleId IdType="pmc">PMC8723827</ArticleId><ArticleId IdType="pubmed">35081335</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature. 2022;603(7902):687–92. doi: 10.1038/s41586-022-04441-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04441-6</ArticleId><ArticleId IdType="pmc">PMC8942849</ArticleId><ArticleId IdType="pubmed">35062015</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paris K, Permar SR. Routine SARS-CoV-2 vaccination for all children. Immunol Rev. 2022;309(1):90–6. doi: 10.1111/imr.13108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13108</ArticleId><ArticleId IdType="pmc">PMC9339529</ArticleId><ArticleId IdType="pubmed">35799475</ArticleId></ArticleIdList></Reference><Reference><Citation>Knisely JM, Buyon LE, Mandt R, Farkas R, Balasingam S, Bok K, et al. Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report. NPJ Vaccines. 2023;8(1):53. doi: 10.1038/s41541-023-00654-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00654-6</ArticleId><ArticleId IdType="pmc">PMC10091310</ArticleId><ArticleId IdType="pubmed">37045860</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Sharp E, Collins J. Studies on the pathogenesis of parainfluenza type 3 virus infection in hamsters. Arch Gesamte Virusforsch. 1968;24(3):203–19. doi: 10.1007/BF01241293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01241293</ArticleId><ArticleId IdType="pubmed">4301657</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilks SH, Muhlemann B, Shen X, Tureli S, LeGresley EB, Netzl A, et al. Mapping SARS-CoV-2 antigenic relationships and serological responses. Science. 2023;382(6666):eadj0070. doi: 10.1126/science.adj0070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adj0070</ArticleId><ArticleId IdType="pubmed">37797027</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602(7898):671–5. doi: 10.1038/s41586-021-04389-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada T, Zhou H, Dcosta BM, Samanovic MI, Chivukula V, Herati RS, et al. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. EBioMedicine. 2022;78:103944. doi: 10.1016/j.ebiom.2022.103944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103944</ArticleId><ArticleId IdType="pmc">PMC9021600</ArticleId><ArticleId IdType="pubmed">35465948</ArticleId></ArticleIdList></Reference><Reference><Citation>Dijokaite-Guraliuc A, Das R, Zhou D, Ginn HM, Liu C, Duyvesteyn HME, et al. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses. Cell Rep. 2023;42(4):112271. doi: 10.1016/j.celrep.2023.112271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112271</ArticleId><ArticleId IdType="pmc">PMC9988707</ArticleId><ArticleId IdType="pubmed">36995936</ArticleId></ArticleIdList></Reference><Reference><Citation>Andeweg SP, de Gier B, Eggink D, van den Ende C, van Maarseveen N, Ali L, et al. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. Nat Commun. 2022;13(1):4738. doi: 10.1038/s41467-022-31838-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31838-8</ArticleId><ArticleId IdType="pmc">PMC9373894</ArticleId><ArticleId IdType="pubmed">35961956</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee IT, Cosgrove CA, Moore P, Bethune C, Nally R, Bula M, et al. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial. Lancet Infect Dis. 2023;23(9):1007–19. doi: 10.1016/S1473-3099(23)00295-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00295-5</ArticleId><ArticleId IdType="pubmed">37348519</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare S, Gurry C, Freitas L, Schultz MB, Bach G, Diallo A, et al. GISAID’s Role in Pandemic Response. China CDC Wkly. 2021;3(49):1049–51. doi: 10.46234/ccdcw2021.255.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2021.255</ArticleId><ArticleId IdType="pmc">PMC8668406</ArticleId><ArticleId IdType="pubmed">34934514</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchholz UJ, Finke S, Conzelmann KK. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol. 1999;73(1):251–9. doi: 10.1128/JVI.73.1.251-259.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.1.251-259.1999</ArticleId><ArticleId IdType="pmc">PMC103829</ArticleId><ArticleId IdType="pubmed">9847328</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T, Teng IT, Olia AS, Cerutti G, Gorman J, Nazzari A, et al. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Rep. 2020;33(4):108322. doi: 10.1016/j.celrep.2020.108322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108322</ArticleId><ArticleId IdType="pmc">PMC7550166</ArticleId><ArticleId IdType="pubmed">33091382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser JA, Liu X, Luongo C, Matsuoka Y, Santos C, Yang L, et al. Intranasal murine pneumonia virus-vectored SARS-CoV-2 vaccine induces mucosal and serum antibodies in macaques. iScience. 2023;26(12):108490. doi: 10.1016/j.isci.2023.108490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.108490</ArticleId><ArticleId IdType="pmc">PMC10746510</ArticleId><ArticleId IdType="pubmed">38144450</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser JA, Nelson CE, Liu X, Park HS, Matsuoka Y, Luongo C, et al. Mucosal prime-boost immunization with live murine pneumonia virus-vectored SARS-CoV-2 vaccine is protective in macaques. Nat Commun. 2024;15(1):3553. doi: 10.1038/s41467-024-47784-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-47784-6</ArticleId><ArticleId IdType="pmc">PMC11053155</ArticleId><ArticleId IdType="pubmed">38670948</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivcec M, Safronetz D, Haddock E, Feldmann H, Ebihara H. Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). J Immunol Methods. 2011;368(1–2):24–35. doi: 10.1016/j.jim.2011.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2011.02.004</ArticleId><ArticleId IdType="pmc">PMC3085612</ArticleId><ArticleId IdType="pubmed">21334343</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Felipe L, Vercruysse T, Sharma S, Ma J, Lemmens V, Van Looveren D, et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature. 2021;590(7845):320–5. doi: 10.1038/s41586-020-3035-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-3035-9</ArticleId><ArticleId IdType="pubmed">33260195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bricker TL, Darling TL, Hassan AO, Harastani HH, Soung A, Jiang X, et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 2021;36(3):109400. doi: 10.1016/j.celrep.2021.109400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109400</ArticleId><ArticleId IdType="pmc">PMC8238649</ArticleId><ArticleId IdType="pubmed">34245672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020;369(6505):812–7. doi: 10.1126/science.abc4776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc4776</ArticleId><ArticleId IdType="pmc">PMC7243369</ArticleId><ArticleId IdType="pubmed">32434946</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000045.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.3.2000045</ArticleId><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–9. doi: 10.1038/s41586-020-2196-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett KS, Nason MC, Flach B, Gagne M, O’Connell S, Johnston TS, et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science. 2021;373(6561):eabj0299. doi: 10.1126/science.abj0299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj0299</ArticleId><ArticleId IdType="pmc">PMC8449013</ArticleId><ArticleId IdType="pubmed">34529476</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>